Whitepapers

Breaking into Solid Tumors with Armored CAR-T Cells

Solid tumors present a major barrier to the wider use of CAR-T cell therapy. One solution is to add genes that secrete cytokines or express cytokine...

Key Takeaways and Insights from the 41st Annual JP Morgan Healthcare Conference

Kineticos Life Sciences attended the Biotech Showcase, an investor networking conference for biotech and life science innovators to meet with and...

Ex Vivo to In Vivo: the Journey of Cell Therapy

Kineticos summarizes the current landscape of in vivo CAR-T cell therapy, to help you stay up to date with the latest trends in CGT....

Autoimmune Disorders: The Next Frontier for CAR-T Therapies

Kineticos summarizes the current landscape of CAR-T cell therapies targeting autoimmune disorders....

Highlights from Cell and Gene Meeting on the Mesa 2022

Kineticos Life Sciences joined more than 2,100 industry leaders for the 2022 Cell & Gene Meeting on the Mesa. Attendees met in person in Carlsbad,...

Viral Vector Demand Presents A Significant Opportunity

Due to increased clinical trial activity, growing needs for scalable manufacturing processes, and backlogged viral vector manufacturers, Lentivirus...

Natural Killer Cells Unique Potential for Cancer Immunotherapy

Natural killer (NK) cell therapeutics are a promising strategy for treating cancer. Compared to T cell approaches, an NK cell therapy would confer...

Visualizing the Future of Contract Development and Manufacturing for Cell and Gene Therapies

“Next-generation medicines, such as cell and gene therapy, are providing significant opportunities for growth in the innovator, CRO, and CDMO...

Ongoing Challenges and Outlook for Rare Disease Drug Development

There are an estimated 7,000 rare diseases that affect 25 to 30 million people in the United States, more than half of whom are children, with...

Cell and Gene Therapies: The Path to Commercialization

As the pharmaceutical industry continues to explore new therapeutic avenues and build on scientific advances in medicine and biosciences,...

Are we Manufacturing the Right T-Cells And a Look at the Future of Oncology Precision Medicine

The final part of the discussion between Kineticos’ Operating Executive, Steve Buckanavage, and Precision Biosciences’ CMO, Christopher Heery M.D.,...

Is Precision Medicine in Oncology Narrowing Patient Population Too Much?

Kineticos’ Operating Executive Steve Buckanavage continues his discussion with Christopher Heery, M.D., CMO at Precision Biosciences, as they tackle...

Can We Create Companion Diagnostics In Oncology With What We Know About Biomarkers?

As we continue our discussion between Steve Buckanavage, Kineticos’ Operating Executive, and Christopher Heery, M.D., CMO at Precision Biosciences,...

Are Checkpoint Inhibitors Impacting How We Cure Disease?

We’re discussing Precision Medicine, and its impact on various segments of the life sciences. Steve Buckanavage, Kineticos Operating Executive,...

A Primer on CAR-T Cell Therapy

In the world of cancer detection, diagnosis, and treatment, there is a continuous stream of new ideas and inventions that alter our understanding of...

A Primer on Regenerative Medicine

The two most groundbreaking and fastest-growing areas of regenerative medicine are cell and gene therapies, with small molecules and biologics,...

A Primer on Gene Editing

Gene editing has recently emerged as a revolutionary scientific tool that may be utilized for therapeutic applications such as curing disease, as...

A Primer on Immuno-Oncology: Part 1

In the first part of the Immuno-Oncology Primer, we will provide an overview of anti-cancer vaccines and cytokines before delving into a discussion...

A Primer on Immuno-Oncology: Part 2 – Targeted Redirection of T Cells

In the second part of this Immuno-Oncology Primer, we will provide an overview of immune checkpoint inhibitors, bispecific T cell engagers, and CAR T...

Primary Research: An Effective Risk Mitigation Tool

The life science industry relies heavily on market research. The evolving nature of the industry and the extremely high financial stakes stress the...